Detailed Narrative
Q1 FY26 Financial Performance and Margin Expansion
Aarti Drugs reported a robust Q1 FY26, with total revenues increasing by 6% year-on-year to INR591 crores. The API business grew by 5% YoY, and the Formulation business saw a 14% YoY growth, reaching INR80 crores. Gross profit margins improved significantly by 130 basis points YoY to 36.8%, primarily due to the normalization of input costs. This translated to a 12% YoY increase in EBITDA to INR74 crores, with EBITDA margins expanding to 12.6%.
Strategic Capacity Expansion and Backward Integration
The company is actively pursuing capacity expansion and backward integration initiatives. The greenfield project at Sayakha, Gujarat, has commenced trial production, focusing on anti-diabetic products and intermediates for internal consumption, expected to contribute to financials from Q3 FY26. Similarly, the Tarapur greenfield site is scaling up salicylic acid production, aiming for 800 tonnes per month soon and eventually 1,600 tonnes per month, with financial contributions also anticipated from Q3 FY26. These projects are crucial for margin improvement and supply chain derisking.
Regulated Market Entry and Global Expansion
Aarti Drugs achieved significant regulatory milestones, including USFDA approval for its oncology facility and UK MHRA approval for its oral solid dosage (OSD) facility. These approvals are expected to drive meaningful growth in regulated markets starting FY27 onwards. The company anticipates commercial supplies to the US market within 9-12 months and expects its Europe market contribution to increase from 12% (FY25) to 15-20%. Efforts are underway to rebuild presence in the US market, leveraging the USFDA approval.
Growth Outlook and Margin Targets
Management projects a 15% CAGR volume growth for FY26 and FY27, with a negative price variation of 4-6% in H1 FY26 expected to normalize in H2. They are targeting EBITDA margins of 15-16% for FY27, driven by higher capacity utilization, improved product mix, and internal sourcing. In optimal conditions with high utilization, EBITDA margins could potentially reach 16.5-17.5%. The formulation business is expected to nearly double to INR550-600 crores by FY28, especially with the commercialization of oncology products.
Capital Allocation and Debt Management
For FY26, Aarti Drugs expects to incur capex in the range of INR150-200 crores, with roughly 50% allocated to new product R&D in the Formulation business (oncology and non-oncology) and the remainder for brownfield expansions and safety improvements. Despite heavy capex and shareholder payouts, the company has maintained its debt-to-equity ratio around 0.42-0.43, and aims to keep it within 0.4-0.7 going forward⏳, demonstrating disciplined financial management.
Salicylic Acid Business Challenges and Strategy
The new salicylic acid plant faces intense competition from Chinese manufacturers, who are dumping products at significantly reduced prices (INR119-120/kg currently, down from INR145-150/kg). Management acknowledges that without anti-dumping duties, achieving 14-15% EBITDA margins in this segment is challenging. The company is actively pursuing anti-dumping duties from the government and aims to break even at 800-900 tonnes per month, with a long-term goal of 1,600 tonnes per month to achieve better margins.